Alnylam Pharmaceuticals Inc annual free cash flow for fiscal TTM was $641 million, an increase of 37.8% from $465 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $641M | $465M | ($43M) | $42M | ($613M) | ($718M) | ($685M) | ($419M) | ($690M) | ($487M) | ($372M) | ($202M) | ($175M) | ($73M) | ($124M) | ($88M) | ($89M) | ($77M) | $55M | $189M | ($30M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $49M | $140M | $313M | $139M | ($127M) | ($104M) | $40M | $116M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More ALNY metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding
All ALNY financial statements → Interactive ALNY charts →
About TickerBase · Data methodology & sources